NCT05133882View on ClinicalTrials.gov

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

133

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

May 15, 2026

Study Completion Date

August 15, 2026

Conditions

Acute Myeloid Leukemia, Adult

Interventions

DRUG

Clifutinib Besylate

The queue 1 is divided into Induction therapy and Consolidation therapy and Maintenance treatment The queue 2 will receive oral Clifutinib Besylate once daily until disease progression or unacceptable toxicity occurs

Trial Locations (1)

310003

RECRUITING

the First Affiliated Hospital,College of Medicine,Zhejiang University, Hanzhou

All Listed Sponsors

lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY